IDEXX Laboratories, Inc.· IDXX
🇺🇸 US · LargeSP500NASDAQ
- Price
- $588.09
- Day
- +3.57%
- Mkt Cap
- $46.39B
- 52W Range
- $518.55 – $769.98
- Volume
- 1.53M
- Beta
- 1.54
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript
Read full article
IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock rose Tuesday after the veterinary diagnostics company reported second-quarter results that topped Wall Street estimates and raised its full-year earnings outlook.
Read full article
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company reports revenues of $1,217 million for the second quarter of 2026, an increase of 10% as reported and 9% organic, driven by Companion Animal Group ("CAG") growth of 9% as reported and organic, Water revenue growth of 15% as reported and 13% organic, and LPD revenue growth of 11% as reported and 9% org.
Read full article
Revenue: Increased approximately 10% as reported and 9% organically.CAG Diagnostics Recurring Revenue: Grew 10.3% organically, with double-digit gains in both t
Read full article
IDEXX Laboratories NASDAQ: IDXX reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing strong recurring diagnostics revenue, product-cost benefits and continued momentum from new product introductions.
Read full article
Idexx Laboratories (IDXX) came out with quarterly earnings of $4.27 per share, beating the Zacks Consensus Estimate of $3.95 per share. This compares to earnings of $3.63 per share a year ago.
Read full article
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
Read full article
Evaluate the expected performance of Idexx (IDXX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read full article
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.
Read full article
American Capital Management Inc. reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 8.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 166,056 shares of the company's stock after selling 15,689 shares during the
Read full article
Bank of Nova Scotia lessened its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 11.1% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 11,124 shares of the company's stock after selling 1,383 shares during the quarter. Bank of Nova Scotia's holdings in IDEXX Laboratories were
Read full article